inVentiv preps for $100m IPO

By Gareth Macdonald contact

- Last updated on GMT

inVentiv preps for $100m IPO

Related tags: U.s. securities and exchange commission

US CRO inVentiv Health has signaled its intention to go public by filing an S1 with the Securities and Exchange Commission (SEC) last night.

According to the S1​, which was filed by parent company inVentiv Group Holding, the Burlington, Massachusetts-based contract services organisation hopes to raise $100m by listing on either the New York Stock Exchange or the NASDAQ Global Market.

inVentiv has been owned by US private equity group Thomas H Lee Partners (THL), which acquired the contractor in 2010 for $1.1bn (€845m).

According to the S1, inVentiv generated net revenues of $1.99bn last year, which is an increase of 10.4% year-on-year.

The document also reveals that the firm's clinical trial business generated revenue of $947m, up 8.9%, while its commercial services unit – which helps drug firms launch products – saw sales of $1bn, which is up 12.3% from 2014.

inVentiv claims to have a client base of more than 550 organizations, including the 20 of the largest global biopharmaceutical companies.

It also says that over 80% of all new molecular entities approved by the US FDA and 70% of those approved by the EMA over the last five years "have been developed or commercialized with our support​."

Related news

Show more

Related products

show more

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 15-Aug-2022 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

Planning Your First-In-Human Trial

Planning Your First-In-Human Trial

Altasciences | 15-Jul-2022 | Technical / White Paper

A first-in-human (FIH) clinical trial is a significant milestone in the development of a potential new drug. A successfully conducted FIH trial provides...

Related suppliers

Follow us


View more